Clinical Trial Update: Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of radiation therapy and SHR-1210 (anti-PD-1) in esophageal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Diseases
• Esophageal Neoplasms
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: Hangzhou Cancer Hospital | Conditions: Esophageal Neoplasms, Esophageal Diseases | Phase 2 | Status: COMPLETED